CHIMERIX INC (CMRX) Stock Price, Quote, News and Overview
NASDAQ:CMRX - Nasdaq - US16934W1062 - Common Stock - Currency: USD
CMRX Quote, Performance and Key Statistics
8.54
-0.01 (-0.12%)
The current stock price of CMRX is 8.54 USD. In the past month the price increased by 0.83%. In the past year, price increased by 865.63%.
CMRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.7 | 321.60B | ||
| AMGN | AMGEN INC | 13.07 | 145.89B | ||
| GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
| ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
| ONC | BEIGENE LTD-ADR | 5.88 | 25.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
| BIIB | BIOGEN INC | 8.02 | 18.58B |
Related stock screener links
About CMRX
Company Profile
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 79 full-time employees. The company went IPO on 2013-04-11. The firm is focused on developing medicines that address unmet medical needs. The firm's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The firm's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides, also includes approximately 3,500 nucleosides.
Company Info
CHIMERIX INC
2505 Meridian Parkway, Suite 100
Durham NORTH CAROLINA 27713 US
CEO: Michael A. Sherman
Employees: 79
Phone: 19198061074
CHIMERIX INC / CMRX FAQ
What is the stock price of CHIMERIX INC today?
The current stock price of CMRX is 8.54 USD. The price decreased by -0.12% in the last trading session.
What is the ticker symbol for CHIMERIX INC stock?
The exchange symbol of CHIMERIX INC is CMRX and it is listed on the Nasdaq exchange.
On which exchange is CMRX stock listed?
CMRX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CHIMERIX INC stock?
11 analysts have analysed CMRX and the average price target is 8.71 USD. This implies a price increase of 2% is expected in the next year compared to the current price of 8.54. Check the CHIMERIX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CHIMERIX INC worth?
CHIMERIX INC (CMRX) has a market capitalization of 801.05M USD. This makes CMRX a Small Cap stock.
How many employees does CHIMERIX INC have?
CHIMERIX INC (CMRX) currently has 79 employees.
What are the support and resistance levels for CHIMERIX INC (CMRX) stock?
CHIMERIX INC (CMRX) has a support level at 8.53 and a resistance level at 8.55. Check the full technical report for a detailed analysis of CMRX support and resistance levels.
Is CHIMERIX INC (CMRX) expected to grow?
The Revenue of CHIMERIX INC (CMRX) is expected to grow by 2198.64% in the next year. Check the estimates tab for more information on the CMRX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CHIMERIX INC (CMRX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CMRX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CMRX, evaluating the profitability, health, valuation and growth aspects
- CHIMERIX INC (CMRX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CHIMERIX INC (CMRX) Sales and EPS estimates to see what analysts future expectations are.
- CHIMERIX INC (CMRX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CHIMERIX INC (CMRX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CHIMERIX INC (CMRX) Stock Chart to make your own analysis
- CHIMERIX INC (CMRX) Latest news and press-releases to stay up to date.
Does CHIMERIX INC (CMRX) stock pay dividends?
CMRX does not pay a dividend.
When does CHIMERIX INC (CMRX) report earnings?
CHIMERIX INC (CMRX) will report earnings on 2025-05-01, before the market open.
What is the Price/Earnings (PE) ratio of CHIMERIX INC (CMRX)?
CHIMERIX INC (CMRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.99).
CMRX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CMRX. When comparing the yearly performance of all stocks, CMRX is one of the better performing stocks in the market, outperforming 99.89% of all stocks.
CMRX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CMRX. CMRX has a great financial health rating, but its profitability evaluates not so good.
CMRX Financial Highlights
Over the last trailing twelve months CMRX reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS decreased by -7.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.54% | ||
| ROE | -72.64% | ||
| Debt/Equity | 0 |
CMRX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 76% to CMRX. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 13.8% and a revenue growth 2198.64% for CMRX